COVID-19 and Dexamethasone: A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection

JAMA. 2020 Aug 18;324(7):623-624. doi: 10.1001/jama.2020.13170.

Authors

William M Stauffer^{1

2}, Jonathan D Alpern^{3

4}, Patricia F Walker^{2

3}

Affiliations

¹ Center for Global Health and Social Responsibility, University of Minnesota, Minneapolis.
² Department of Medicine, Global Medicine, University of Minnesota, Minneapolis.
³ HealthPartners Institute, Bloomington, Minnesota.
⁴ HealthPartners Travel and Tropical Medicine Center, St Paul, Minnesota.

PMID: 32761166
DOI: 10.1001/jama.2020.13170

No abstract available

MeSH terms

Animals
COVID-19 / complications
COVID-19 Drug Treatment*
Dexamethasone / adverse effects*
Dexamethasone / therapeutic use
Humans
Immunocompromised Host
Strongyloides stercoralis
Strongyloidiasis / etiology
Strongyloidiasis / prevention & control*

Substances

Dexamethasone